☆ 4.7 Article

Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients

EUROPEAN HEART JOURNAL (2023)

Related references

Note: Only part of the references are listed.

Article Hematology

Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma

Raphael E. Steiner et al.

Summary: This study retrospectively reviewed the characteristics and outcomes of adult patients with relapsed/refractory large 6-cell lymphoma treated with SOC axi-cel or tisa-cel. It found that 16% of these patients experienced a 30-day major adverse CV event (MACE), including arrhythmias, heart failure, cerebrovascular accidents, and myocardial infarctions. Factors such as age ≥60 years, early and severe cytokine release syndrome (CRS), prolonged CRS, and use of tocilizumab were significantly associated with an increased risk of 30-day MACE.

HAEMATOLOGICA (2022)

Add to Collection

Article Medicine, General & Internal

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

F. L. Locke et al.

Summary: This international phase 3 trial showed that axicabtagene ciloleucel therapy significantly improved event-free survival and response in patients with early relapsed or refractory large B-cell lymphoma compared to standard care, despite the expected high-grade toxic effects.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Review Cardiac & Cardiovascular Systems

Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies

Matthias Totzeck et al.

Summary: Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary advance in cancer treatment, but it can lead to cytokine release syndrome and cardiovascular events.

EUROPEAN HEART JOURNAL (2022)

Add to Collection

Article Medicine, General & Internal

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

Manali Kamdar et al.

LANCET (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy

Adam Goldman et al.

Summary: This study identified an association between CAR-T therapy and various CPAEs, including tachyarrhythmias, cardiomyopathy, pericardial and pleural disorders, and venous thromboembolic events. These findings should be considered in the assessment and monitoring of CAR-T therapy recipients.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Patient Characteristics and Clinical Outcomes of Type 1 Versus Type 2 Myocardial Infarction

Cian P. McCarthy et al.

Summary: The study found that patients with type 2 MI, compared to those with type 1 MI, were older, had a higher proportion of women, and had higher prevalence of heart failure, kidney disease, and atrial fibrillation. Patients with type 2 MI had lower rates of coronary angiography, percutaneous coronary intervention, and coronary artery bypass grafting, but also lower risks of in-hospital mortality and 30-day MI readmission.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Add to Collection

Review Oncology

Monitoring for Chemotherapy-Related Cardiotoxicity in the Form of Left Ventricular Systolic Dysfunction: A Review of Current Recommendations

Jeremy R. Stone et al.

Summary: Cardiotoxicity is a well-established complication of cancer therapeutics, with left ventricular dysfunction being a prominent effect. Monitoring strategies for potentially cardiotoxic treatments are crucial for patient outcomes, with recommendations varying between guidelines for screening and monitoring. Echocardiography and cardiac magnetic resonance imaging are key modalities for surveillance, while laboratory biomarkers and myocardial strain imaging can help detect subclinical cardiotoxicity. Future studies are needed to evaluate surveillance recommendations and develop specific guidelines for novel cancer therapeutics.

JCO ONCOLOGY PRACTICE (2021)

Add to Collection

Review Oncology

Monitoring for Chemotherapy-Related Cardiotoxicity in the Form of Left Ventricular Systolic Dysfunction: A Review of Current Recommendations

Jeremy R. Stone et al.

Summary: Cardiotoxicity is a common complication of cancer therapies, leading to left ventricular dysfunction, monitoring strategies and specific recommendations are important for at-risk patients. Echocardiography and cardiac magnetic resonance imaging are essential monitoring methods, with laboratory biomarkers playing a role in detecting potential cardiotoxicity.

JCO ONCOLOGY PRACTICE (2021)

Add to Collection

Letter Oncology

Myocarditis Surveillance With High-Sensitivity Troponin I During Cancer Treatment With Immune Checkpoint Inhibitors

Sarah Waliany et al.

JACC: CARDIOONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Jeremy S. Abramson et al.

LANCET (2020)

Add to Collection

Review Medicine, General & Internal

Cytokine Storm

David C. Fajgenbaum et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Letter Cardiac & Cardiovascular Systems

Chimeric Antigen Receptor T-Cell Therapy-Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma

Sarju Ganatra et al.

CIRCULATION (2020)

Add to Collection

Article Oncology

Cardiovascular Effects of CAR T Cell Therapy A Retrospective Study

Benedicte Lefebvre et al.

JACC: CARDIOONCOLOGY (2020)

Add to Collection

Article Hematology

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Daniel W. Lee et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart JACC Council Perspectives

Sarju Ganatra et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)

Raza M. Alvi et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

Syed S. Mahmood et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

S. L. Maude et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

S. S. Neelapu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Oncology

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

David T. Teachey et al.

CANCER DISCOVERY (2016)

Add to Collection

Article Cardiac & Cardiovascular Systems

Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy

Daniela Cardinale et al.

CIRCULATION (2015)

Add to Collection

Article Oncology

Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation

Daniela Cardinale et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

Add to Collection

Article Cardiac & Cardiovascular Systems

Anthracycline-Induced Cardiomyopathy Clinical Relevance and Response to Pharmacologic Therapy

Daniela Cardinale et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.